Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs. The new facility will produce biologic drugs and Keytruda,

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in Ireland and Singapore, in addition to its arrangements with contract manufacturers. Last year, Keytruda generated sales of $29.5 billion, accounting for 46% of the company’s revenue of $64.2 billion.